PharmaVigilant Enhances eTMF System With Groundbreaking Functionality; Competitive Gap Widens Company Unveils I-Vault 2.5 for En

PharmaVigilant Enhances eTMF System With Groundbreaking Functionality; Competitive Gap Widens Company Unveils I-Vault 2.5 for Enhanced Reporting, Tracking and E-mail Functionality

WESTBOROUGH, MA -- (Marketwire) -- 07/27/10 -- PharmaVigilant, a clinical trial technology provider, today unveiled I-Vault 2.5, the enhanced version of its industry-leading electronic Trial Master File (TMF) system. This new version offers easier access to the critical trial data that sponsors need to make important decisions related to their clinical trial quickly and effectively. I-Vault 2.5 improves usability, administration and notification capabilities for seamless site startup, site closeout and IRB submissions, drastically reducing costly trial delays and roadblocks.

By offering unlimited rights and roles and enabling global scalability, PharmaVigilant's enhanced eTMF system offers improved accuracy and analysis of trial data. Flexibility is key, particularly for complex trials, and I-Vault 2.5 allows each sponsor to determine which trial documents they wish to collect and how they would like them organized. This level of customization makes it easier for sponsors to adhere to study startup and closeout timelines while saving time by making disparate data easier and faster for sponsors to find.

"Sponsors need to convert their trial master files yesterday, so the need for robust, full-function products that can scale globally are in demand in the market. PharmaVigilant is committed to aggressive investments in our technology, and as a result we are widening the gap between ours and our competitors' offerings," said James DeSanti, founder and CEO of PharmaVigilant. "With this newest version of I-Vault 2.5, our clients can better isolate trial inefficiencies and achieve significantly higher quality and cost savings. PharmaVigilant continues to produce innovative and unique technologies that are changing the landscape of the clinical trial industry."

The newest version of I-Vault 2.5 includes key features such as:

Enhanced e-mail notifications - allows trial sponsors to subscribe all users of a certain role to a notification.

Enhanced document tracking capabilities - automatically send e-mails to designated users when an action has occurred on the select document they are tracking.

Improved reporting functionality - users can view their documents in charts broken down by status, site or type, improving transparency and organization of files.

Separated signed and approval status - provides increased visibility for users.

PharmaVigilant offers a full suite of clinical trial technology offerings including Electronic Data Capture (EDC), data warehousing, study building (I-Builder 2.0), Electronic Trial Master File System (eTMF), Remote Source Document Verification (rSDV), study administration and an automated site payment system. PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies. The technology has supported more than 200,000 patients in 14 countries across North America, South America, Europe, and Asia and continues to expand rapidly.

About PharmaVigilant:

Based in Westborough, Mass., PharmaVigilant is a SaaS company founded in 2005 to provide broader technologies to streamline the clinical trial process for biopharmaceutical companies. Its full suite of patient-based technology automates the collection, management, and analysis of clinical trial data and most importantly puts that data in the sponsors' hands when and how they want it. Sponsors rely on PharmaVigilant to ease the regulatory and FDA submission and approval process and ultimately go-to-market more quickly with top quality drugs. For more information, visit www.pharmavigilant.com :  .

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.